Skip to main content
Premium Trial:

Request an Annual Quote

OGS Inks Second Deal with Pfizer

NEW YORK, Jan. 7-Oxford GlycoSciences said today that it has expanded its proteomics contract with Pfizer.


OGS first struck a deal with Pfizer in 1998, a collaboration intended to identify new biomarkers and drug targets in Alzheimer's disease, arteriosclerosis and other diseases.


The disease area and financial terms of the new agreement were not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.